Cross-Reactivity to Kynureninase Tolerizes B Cells That Express the HIV-1 Broadly Neutralizing Antibody 2F5

被引:10
作者
Finney, Joel [1 ]
Yang, Guang [1 ]
Kuraoka, Masayuki [1 ]
Song, Shengli [1 ]
Nojima, Takuya [1 ]
Verkoczy, Laurent [2 ]
Kitamura, Daisuke [3 ]
Haynes, Barton F. [1 ,4 ]
Kelsoe, Garnett [1 ,4 ]
机构
[1] Duke Univ, Dept Immunol, Durham, NC 27710 USA
[2] San Diego Biomed Res Inst, San Diego, CA 92121 USA
[3] Tokyo Univ Sci, Res Inst Biomed Sci, Noda, Chiba 2780022, Japan
[4] Duke Univ, Human Vaccine Inst, Durham, NC 27710 USA
基金
美国国家卫生研究院;
关键词
MONOCLONAL-ANTIBODIES; GENE REPLACEMENT; CLONAL DELETION; SELF-TOLERANCE; MEMBRANE; AUTOREACTIVITY; LYMPHOCYTES; ANTIGEN; MICE; IDENTIFICATION;
D O I
10.4049/jimmunol.1900069
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
2F5 is an HIV-1 broadly neutralizing Ab that also binds the autoantigens kynureninase (KYNU) and anionic lipids. Generation of 2F5-like Abs is proscribed by immune tolerance, but it is unclear which autospecificity is responsible. We sampled the BCR repertoire of 2F5 knock-in mice before and after the first and second tolerance checkpoints. Nearly all small pre-B (precheck-point) and 35-70% of anergic peripheral B cells (postcheckpoint) expressed the 2F5 BCR and maintained KYNU, lipid, and HIV-1 gp41 reactivity. In contrast, all postcheckpoint mature follicular (MF) B cells had undergone L chain editing that purged KYNU and gp41 binding but left lipid reactivity largely intact. We conclude that specificity for KYNU is the primary driver of tolerization of 2F5-expressing B cells. The MF and anergic B cell populations favored distinct collections of editor L chains; surprisingly, however, MF and anergic B cells also frequently expressed identical BCRs. These results imply that BCR autoreactivity is the primary determinant of whether a developing B cell enters the MF or anergic compartments, with a secondary role for stochastic factors that slightly mix the two pools. Our study provides mechanistic insights into how immunological tolerance impairs humoral responses to HIV-1 and supports activation of anergic B cells as a potential method for HIV-1 vaccination.
引用
收藏
页码:3268 / 3281
页数:14
相关论文
共 36 条
  • [21] Characterization of antibody responses against the 2F5 epitope ELDKWA sing HIV-1 Env-mediated membrane fusion and neutralization assays
    Cao Y.
    Chen Y.
    Tsinghua Science and Technology, 2010, 15 (04) : 447 - 451
  • [23] Common Tolerance Mechanisms, but Distinct Cross-Reactivities Associated with gp41 and Lipids, Limit Production of HIV-1 Broad Neutralizing Antibodies 2F5 and 4E10
    Chen, Yao
    Zhang, Jinsong
    Hwang, Kwan-Ki
    Bouton-Verville, Hilary
    Xia, Shi-Mao
    Newman, Amanda
    Ouyang, Ying-Bin
    Haynes, Barton F.
    Verkoczy, Laurent
    JOURNAL OF IMMUNOLOGY, 2013, 191 (03) : 1260 - 1275
  • [24] HIV-1 Envelope gp41 Antibodies Can Originate from Terminal Ileum B Cells that Share Cross-Reactivity with Commensal Bacteria
    Trama, Ashley M.
    Moody, M. Anthony
    Alam, S. Munir
    Jaeger, Frederick H.
    Lockwood, Bradley
    Parks, Robert
    Lloyd, Krissey E.
    Stolarchuk, Christina
    Scearce, Richard
    Foulger, Andrew
    Marshall, Dawn J.
    Whitesides, John F.
    Jeffries, Thomas L., Jr.
    Wiehe, Kevin
    Morris, Lynn
    Lambson, Bronwen
    Soderberg, Kelly
    Hwang, Kwan-Ki
    Tomaras, Georgia D.
    Vandergrift, Nathan
    Jackson, Katherine J. L.
    Roskin, Krishna M.
    Boyd, Scott D.
    Kepler, Thomas B.
    Liao, Hua-Xin
    Haynes, Barton F.
    CELL HOST & MICROBE, 2014, 16 (02) : 215 - 226
  • [25] Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes
    Matyas, Gary R.
    Wieczorek, Lindsay
    Beck, Zoltan
    Ochsenbauer-Jambor, Christina
    Kappes, John C.
    Michael, Nelson L.
    Polonis, Victoria R.
    Alving, Carl R.
    AIDS, 2009, 23 (16) : 2069 - 2077
  • [26] Artificial Anti-HIV-1 Immunogen Comprising Epitopes of Broadly Neutralizing Antibodies 2F5, 10E8, and a Peptide Mimic of VRC01 Discontinuous Epitope
    Rudometov, Andrey P.
    Chikaev, Anton N.
    Rudometova, Nadezhda B.
    Antonets, Denis, V
    Lomzov, Alexander A.
    Kaplina, Olga N.
    Ilyichev, Alexander A.
    Karpenko, Larisa, I
    VACCINES, 2019, 7 (03)
  • [27] Broadly Neutralizing Antibody VRC01 Prevents HIV-1 Transmission from Plasmacytoid Dendritic Cells to CD4 T Lymphocytes
    Su, Bin
    Lederle, Alexandre
    Laumond, Geraldine
    Ducloy, Camille
    Schmidt, Sylvie
    Decoville, Thomas
    Moog, Christiane
    JOURNAL OF VIROLOGY, 2014, 88 (18) : 10975 - 10981
  • [28] Structure and Immunogenicity of a Peptide Vaccine, Including the Complete HIV-1 gp41 2F5 Epitope IMPLICATIONS FOR ANTIBODY RECOGNITION MECHANISM AND IMMUNOGEN DESIGN
    Serrano, Soraya
    Araujo, Aitziber
    Apellaniz, Beatriz
    Bryson, Steve
    Carravilla, Pablo
    de la Arada, Igor
    Huarte, Nerea
    Rujas, Edurne
    Pai, Emil F.
    Arrondo, Jose L. R.
    Domene, Carmen
    Angeles Jimenez, Maria
    Nieva, Jose L.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (10) : 6565 - 6580
  • [29] Association of variations of NAb 2F5 and 4E10 epitopes and disease progression in Chinese antiretroviral treatment-naive patients infected with HIV-1 clade B'
    Zhang Xiao-li
    Han Xiao-xu
    Dai Di
    Bao Ming-jia
    Xu Dong-bing
    Zhang Zi-ning
    Wang Ya-nan
    Zhao Min
    Bice, Tristan
    Jiang Yong-jun
    Shang Hong
    CHINESE MEDICAL JOURNAL, 2010, 123 (23) : 3406 - 3411
  • [30] Fragments of the V1/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PG9 antibody
    Morales, Javier F.
    Yu, Bin
    Perez, Gerardo
    Mesa, Kathryn A.
    Alexander, David L.
    Berman, Phillip W.
    MOLECULAR IMMUNOLOGY, 2016, 77 : 14 - 25